Enterprise Value

362.7M

Cash

297.5M

Avg Qtr Burn

-12.55M

Short % of Float

8.49%

Insider Ownership

2.10%

Institutional Own.

93.61%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
TERN-501 (THR-B Agonist) +TERN-101 (FXR agonist) Details
Non-alcoholic steatohepatitis

Big Mover™

Susp. Mover™

Phase 2a

Data readout

TERN-101 (FXR agonist) Details
Non-alcoholic steatohepatitis

Phase 2a

Update

TERN-201 (VAP-1 inhibitor) Details
Non-alcoholic steatohepatitis

Phase 1b

Update

Phase 1

Data readout

TERN-701 (Allosteric BCR-ABL inhib) Details
Chronic myelomonocytic leukemia

Phase 1

Interim update